All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $50,033 | $48,194 | $48,300 | $45,006 | $46,159 | $46,385 |
| Cost of Revenue | $15,389 | $13,936 | $13,968 | $10,693 | $10,137 | $9,940 |
| Gross Profit | $34,644 | $34,258 | $34,332 | $34,313 | $36,022 | $36,445 |
| General & Administrative | $7,323 | $7,267 | $8,414 | $7,772 | $7,814 | $7,690 |
| Research & Development | $10,559 | $9,951 | $11,159 | $9,299 | $9,509 | $10,195 |
| Provision for Doubtful Accounts | – | – | $41 | $14 | $7 | $4 |
| Total Operating Expenses | $38,702 | $38,866 | $56,679 | $36,566 | $38,446 | $38,287 |
| Operating Income | $11,331 | $9,328 | -$8,379 | $8,440 | $7,713 | $8,098 |
| Non-Operating | ||||||
| Net Interest Expense | -$1,182 | -$1,305 | -$1,469 | -$717 | -$1,061 | -$1,295 |
| Other Non-Operating Income (Expense) | $1,183 | $1,305 | $1,469 | $717 | $1,061 | $1,295 |
| EBT (Earnings Before Tax) | $11,332 | $9,328 | -$8,379 | $8,440 | $7,713 | $8,098 |
| Income Tax Expense | $2,089 | $2,272 | $554 | $400 | $1,368 | $1,084 |
| Minority Interest | – | – | – | – | $18 | $20 |
| Net Income | ||||||
| Net Income | $9,243 | $7,054 | -$8,948 | $8,025 | $6,327 | $6,994 |
| Per Share Data | ||||||
| Revenue Per Share | $24.37 | $23.64 | $23.83 | $21.66 | $21.51 | $20.66 |
| EPS (Basic) | $4.53 | $3.47 | -$4.41 | $3.88 | $2.97 | $3.15 |
| EPS (Diluted) | $4.52 | $3.46 | -$4.41 | $3.86 | $2.95 | $3.12 |
| Weighted Avg Shares (Basic) | 2.04B | 2.03B | 2.03B | 2.07B | 2.13B | 2.22B |
| Weighted Avg Shares (Diluted) | 2.05B | 2.04B | 2.03B | 2.08B | 2.15B | 2.25B |
| Shares Outstanding | 2.05B | 2.04B | 2.03B | 2.08B | 2.15B | 2.25B |
| Dividends Per Share | $2.52 | $2.49 | $2.42 | $2.31 | $2.19 | $2.01 |
Bristol-Myers Squibb (BMY) financials: revenue, profit and margins
Bristol-Myers Squibb (BMY) generated about $50.0 billion in revenue and $9.2 billion in net income (a 18.5% net margin) over the trailing twelve months, growing at roughly 2.5% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
What is Bristol-Myers Squibb's (BMY) revenue?+
Bristol-Myers Squibb generated about $50.0 billion in revenue over the trailing twelve months. Revenue has grown at roughly 2.5% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Bristol-Myers Squibb profitable?+
Yes, Bristol-Myers Squibb reported about $9.2 billion in net income over the trailing twelve months, a net profit margin of roughly 18.5%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Bristol-Myers Squibb's profit margins?+
Bristol-Myers Squibb runs a gross margin of about 69.2%, an operating margin of about 22.6%, a net margin of about 18.5%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is Bristol-Myers Squibb growing?+
Bristol-Myers Squibb's revenue has compounded at roughly 2.5% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside BMY's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 21 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 31 Oct 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Pharmaceutical Preparations · Pick stocks to compare with BMY
Held by ETFs
BMY is in 428 US ETFs. The largest of them, with BMY's weight in each:
Spot a number that looks wrong? Check it in BMY's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BMY
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.